Decheng Capital’s NewAmsterdam Pharma NAMS Stock Holding History

Decheng Capital’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.99M	Sell	176,887 -148,170	-46%	-$4.88M	0.82%	12
2026 Q1	$10.4M	Sell	325,057 -267,000	-45%	-$8.7M	1.57%	7
2025 Q4	$20.8M	Sell	592,057 -64,994	-10%	-$2.37M	2.79%	6
2025 Q3	$18.7M	Sell	657,051 -112,949	-15%	-$2.71M	3.26%	5
2025 Q2	$13.9M	Hold	770,000	–	–	3.52%	5
2025 Q1	$15.8M	Hold	770,000	–	–	4.42%	5
2024 Q4	$19.8M	Buy	770,000 +180,000	+31%	+$3.82M	4.24%	4
2024 Q3	$9.79M	Buy	590,000 +190,000	+48%	+$3.29M	2.32%	9
2024 Q2	$7.68M	Buy	+400,000	New	+$8.02M	2.35%	10

Other funds holding NAMS

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Decheng Capital's NAMS Position: Q2 2026 in Review

Decheng Capital reduced its NewAmsterdam Pharma (NAMS) stake by 46% in Q2 2026, selling an estimated $4.88M and leaving 176,887 shares worth $5.99M. The position accounts for 0.82% of the portfolio, ranked #12.

Decheng Capital first reported a position in NAMS in Q2 2024 and has held it in 9 quarters since. The position peaked at $20.8M in Q4 2025. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Decheng Capital held 176,887 shares of NewAmsterdam Pharma worth $5.99M as of Q2 2026.
Decheng Capital sold 148,170 NewAmsterdam Pharma shares in Q2 2026, an estimated $4.88M.
NewAmsterdam Pharma made up 0.82% of Decheng Capital's portfolio in Q2 2026, its #12 holding.
Decheng Capital first reported a position in NewAmsterdam Pharma in Q2 2024 and has held it in 9 quarters since.
Decheng Capital's NewAmsterdam Pharma position peaked at $20.8M in Q4 2025.
194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Decheng Capital's 13F filing for Q2 2026, filed 14 Aug 2026.